{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:35:36Z","timestamp":1792103736844,"version":"4.4.0"},"reference-count":548,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone turnover markers (BTMs) are used widely, in both research and clinical practice. In the last 20 years, much experience has been gained in measurement and interpretation of these markers, which include commonly used bone formation markers (bone alkaline phosphatase, osteocalcin, and procollagen I N-propeptide); and commonly used resorption markers (serum C-telopeptides of type I collagen, urinary N-telopeptides of type I collagen, and tartrate-resistant acid phosphatase type 5b). BTMs are usually measured by enzyme-linked immunosorbent assay or automated immunoassay. Sources contributing to BTM variability include uncontrollable factors (eg, age, gender, ethnicity) and controllable factors, particularly relating to collection conditions (eg, fasting\/feeding state, and timing relative to circadian rhythms, menstrual cycling, and exercise). Pregnancy, season, drugs, and recent fracture(s) can also affect BTMs. BTMs correlate with other methods of assessing bone turnover, such as bone biopsies and radiotracer kinetics, and can usefully contribute to diagnosis and management of several diseases such as osteoporosis, osteomalacia, Paget\u2019s disease, fibrous dysplasia, hypophosphatasia, primary hyperparathyroidism, and chronic kidney disease\u2013mineral bone disorder.<\/jats:p>","DOI":"10.1210\/endrev\/bnac031","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T23:26:42Z","timestamp":1670887602000},"page":"417-473","source":"Crossref","is-referenced-by-count":386,"title":["Bone Turnover Markers: Basic Biology to Clinical Applications"],"prefix":"10.1210","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-2095","authenticated-orcid":false,"given":"Marian","family":"Schini","sequence":"first","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield , Sheffield S10 2HQ , UK"},{"name":"Metabolic Bone Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield S5 7AU , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiane","family":"Vilaca","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield , Sheffield S10 2HQ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-2001","authenticated-orcid":false,"given":"Fatma","family":"Gossiel","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield , Sheffield S10 2HQ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syazrah","family":"Salam","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield , Sheffield S10 2HQ , UK"},{"name":"Metabolic Bone Centre, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield S5 7AU , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-3366","authenticated-orcid":false,"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield , Sheffield S10 2HQ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"2023050817150009100_bnac031-B1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fbioe.2018.00134","article-title":"In vitro models of bone remodelling and associated disorders","volume":"6","author":"Owen","year":"2018","journal-title":"Front Bioeng Biotechnol"},{"issue":"11","key":"2023050817150009100_bnac031-B2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2023050817150009100_bnac031-B3","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1359\/jbmr.2001.16.9.1583","article-title":"The bone remodeling compartment: a circulatory function for bone lining cells","volume":"16","author":"Parfitt","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"4-5","key":"2023050817150009100_bnac031-B4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/THC-2006-144-520","article-title":"Dynamic short crack growth in cortical bone","volume":"14","author":"Hazenberg","year":"2006","journal-title":"Technol Health Care"},{"issue":"1","key":"2023050817150009100_bnac031-B5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S8756-3282(01)00642-1","article-title":"Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression","volume":"30","author":"Parfitt","year":"2002","journal-title":"Bone"},{"key":"2023050817150009100_bnac031-B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116148","article-title":"Aspects of intercellular communication in bone and implications in therapy","volume":"153","author":"John Martin","year":"2021","journal-title":"Bone"},{"issue":"1","key":"2023050817150009100_bnac031-B7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev.bioeng.8.061505.095721","article-title":"Biomechanical and molecular regulation of bone remodeling","volume":"8","author":"Robling","year":"2006","journal-title":"Annu Rev Biomed Eng"},{"issue":"3","key":"2023050817150009100_bnac031-B8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr Rev"},{"issue":"5","key":"2023050817150009100_bnac031-B9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beem.2008.07.006","article-title":"Bone remodelling: its local regulation and the emergence of bone fragility","volume":"22","author":"Martin","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2023050817150009100_bnac031-B10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1172\/JCI33612","article-title":"Building bone to reverse osteoporosis and repair fractures","volume":"118","author":"Khosla","year":"2008","journal-title":"J Clin Invest"},{"issue":"52","key":"2023050817150009100_bnac031-B11","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0805133106","article-title":"Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate","volume":"105","author":"Pederson","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2023050817150009100_bnac031-B12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.cellbio.14.1.59","article-title":"Mechanisms of Wnt signaling in development","volume":"14","author":"Wodarz","year":"1998","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"4983","key":"2023050817150009100_bnac031-B13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/206489a0","article-title":"Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling","volume":"206","author":"Hattner","year":"1965","journal-title":"Nature"},{"issue":"3","key":"2023050817150009100_bnac031-B14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00198-002-1329-4","article-title":"Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN","volume":"14","author":"Sowers","year":"2003","journal-title":"Osteoporos Int"},{"issue":"7","key":"2023050817150009100_bnac031-B15","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1210\/jc.2012-4113","article-title":"Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity","volume":"98","author":"Sowers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023050817150009100_bnac031-B16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02013227","article-title":"Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age","volume":"26","author":"Lips","year":"1978","journal-title":"Calcif Tiss Int"},{"issue":"5","key":"2023050817150009100_bnac031-B18","first-page":"549","article-title":"Skeletal progenitor cells and ageing human populations","volume":"94","author":"Oreffo","year":"1998","journal-title":"ClinSci(Lond)"},{"issue":"6","key":"2023050817150009100_bnac031-B19","first-page":"964","article-title":"Menopausal changes in bone remodeling","volume":"92","author":"Heaney","year":"1978","journal-title":"J Lab Clin Med"},{"issue":"4","key":"2023050817150009100_bnac031-B20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/jcem-67-4-741","article-title":"Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers","volume":"67","author":"Eastell","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"issue":"9727","key":"2023050817150009100_bnac031-B21","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(10)60320-0","article-title":"Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study","volume":"375","author":"Zebaze","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"2023050817150009100_bnac031-B22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00003086-196907000-00006","article-title":"Population similarities in the onset and rate of adult endosteal bone loss","volume":"65","author":"Garn","year":"1969","journal-title":"Clin Orthop"},{"issue":"12","key":"2023050817150009100_bnac031-B23","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1359\/jbmr.060904","article-title":"Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women","volume":"21","author":"Szulc","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023050817150009100_bnac031-B24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S8756-3282(00)00353-7","article-title":"Structural and cellular changes during bone growth in healthy children","volume":"27","author":"Parfitt","year":"2000","journal-title":"Bone"},{"key":"2023050817150009100_bnac031-B25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115879","article-title":"Reference intervals in Danish children and adolescents for bone turnover markers carboxy-terminal cross-linked telopeptide of type I collagen (\u03b2-CTX), pro-collagen type I N-terminal propeptide (PINP), osteocalcin (OC) and bone-specific alkaline phosphatase (bone ALP)","volume":"146","author":"Diemar","year":"2021","journal-title":"Bone"},{"issue":"4","key":"2023050817150009100_bnac031-B26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/jbmr.2388","article-title":"Trabecular and cortical microstructure and fragility of the distal radius in women","volume":"30","author":"Bala","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023050817150009100_bnac031-B27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1677\/joe.1.06059","article-title":"Role of oestrogen in the regulation of bone turnover at the menarche","volume":"185","author":"Eastell","year":"2005","journal-title":"J Endocrinol"},{"issue":"4","key":"2023050817150009100_bnac031-B28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2007.12.218","article-title":"Establishing a reference range for bone turnover markers in young, healthy women","volume":"42","author":"Glover","year":"2008","journal-title":"Bone"},{"key":"2023050817150009100_bnac031-B29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116347","article-title":"Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Osteoporosis in Sheffield Evaluation)","volume":"158","author":"Mattia","year":"2022","journal-title":"Bone"},{"issue":"6","key":"2023050817150009100_bnac031-B30","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.7326\/0003-4819-66-6-1243","article-title":"Relationship of hydroxyproline excretion in urine to collagen metabolism","volume":"66","author":"Prockop","year":"1967","journal-title":"Ann Intern Med"},{"issue":"2","key":"2023050817150009100_bnac031-B31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0003-2697(84)90101-5","article-title":"Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography","volume":"137","author":"Eyre","year":"1984","journal-title":"Anal Biochem"},{"issue":"5","key":"2023050817150009100_bnac031-B32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1172\/JCI109954","article-title":"New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease","volume":"66","author":"Price","year":"1980","journal-title":"J Clin Invest"},{"issue":"6 Pt 1","key":"2023050817150009100_bnac031-B33","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/clinchem\/42.6.947","article-title":"Immunoassay for intact amino-terminal propeptide of human type I procollagen","volume":"42","author":"Melkko","year":"1996","journal-title":"Clin Chem"},{"issue":"7","key":"2023050817150009100_bnac031-B34","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1359\/jbmr.1997.12.7.1028","article-title":"Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen","volume":"12","author":"Bonde","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2023050817150009100_bnac031-B35","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/jbmr.5650071119","article-title":"A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine","volume":"7","author":"Hanson","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2023050817150009100_bnac031-B36","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1359\/jbmr.2000.15.7.1337","article-title":"Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption","volume":"15","author":"Halleen","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023050817150009100_bnac031-B37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/clinchem\/47.4.694","article-title":"Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis","volume":"47","author":"Garnero","year":"2001","journal-title":"Clin Chem"},{"issue":"3","key":"2023050817150009100_bnac031-B38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12291-013-0408-y","article-title":"Alkaline phosphatase: an overview","volume":"29","author":"Sharma","year":"2014","journal-title":"Indian J Clin Biochem"},{"issue":"Pt 2","key":"2023050817150009100_bnac031-B39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj3210297","article-title":"Human tissue non-specific alkaline phosphatases: sugar-moiety-induced enzymic and antigenic modulations and genetic aspects","volume":"321","author":"Nosjean","year":"1997","journal-title":"Biochem J"},{"issue":"2","key":"2023050817150009100_bnac031-B40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0009-8981(01)00584-8","article-title":"Quantitation of soluble and skeletal alkaline phosphatase, and insoluble alkaline phosphatase anchor-hydrolase activities in human serum","volume":"311","author":"Anh","year":"2001","journal-title":"Clin Chim Acta"},{"issue":"4","key":"2023050817150009100_bnac031-B41","first-page":"1046","article-title":"Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease","volume":"77","author":"Garnero","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00223-015-0079-1","article-title":"Alkaline Phosphatase and Hypophosphatasia","volume":"98","author":"Millan","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"2023050817150009100_bnac031-B43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cca.2019.11.012","article-title":"Bone alkaline phosphatase: an important biomarker in chronic kidney disease - mineral and bone disorder","volume":"501","author":"Nizet","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"6","key":"2023050817150009100_bnac031-B44","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/01.ASN.0000128955.83129.9C","article-title":"Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin","volume":"15","author":"Lomashvili","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2023050817150009100_bnac031-B45","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/jbmr.1901","article-title":"In vivo overexpression of tissue-nonspecific alkaline phosphatase increases skeletal mineralization and affects the phosphorylation status of osteopontin","volume":"28","author":"Narisawa","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023050817150009100_bnac031-B46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/REP-13-0153","article-title":"Alkaline phosphatases contribute to uterine receptivity, implantation, decidualization, and defense against bacterial endotoxin in hamsters","volume":"146","author":"Lei","year":"2013","journal-title":"Reproduction"},{"issue":"1","key":"2023050817150009100_bnac031-B47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jbmr.2606","article-title":"FGF23 Regulates Bone Mineralization in a 1,25(OH)2 D3 and Klotho-Independent Manner","volume":"31","author":"Murali","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2023050817150009100_bnac031-B48","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144855","article-title":"Alkaline phosphatase: Structure, expression and its function in bone mineralization","volume":"754","author":"Vimalraj","year":"2020","journal-title":"Gene"},{"issue":"10","key":"2023050817150009100_bnac031-B49","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"366","author":"Whyte","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2023050817150009100_bnac031-B50","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.72.10.3925","article-title":"Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue","volume":"72","author":"Hauschka","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2023050817150009100_bnac031-B51","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1073\/pnas.73.5.1447","article-title":"Characterization of a gamma-carboxyglutamic acid-containing protein from bone","volume":"73","author":"Price","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl_4","key":"2023050817150009100_bnac031-B52","doi-asserted-by":"crossref","first-page":"1168S","DOI":"10.1093\/jn\/126.suppl_4.1168S","article-title":"Changing phosphorus content of the U.S. diet: potential for adverse effects on bone","volume":"126","author":"Calvo","year":"1996","journal-title":"J Nutr"},{"issue":"1","key":"2023050817150009100_bnac031-B53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nrendo.2012.201","article-title":"The role of osteocalcin in human glucose metabolism: marker or mediator?","volume":"9","author":"Booth","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2023050817150009100_bnac031-B54","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/en.2003-0990","article-title":"Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength","volume":"145","author":"O\u2019Brien","year":"2004","journal-title":"Endocrinology"},{"issue":"5","key":"2023050817150009100_bnac031-B55","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1210\/jcem-64-5-954","article-title":"Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis","volume":"64","author":"Brown","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"2023050817150009100_bnac031-B56","doi-asserted-by":"crossref","first-page":"12760","DOI":"10.1016\/S0021-9258(18)42960-2","article-title":"Origin of the vitamin k-dependent bone protein found in plasma and its clearance by kidney and bone","volume":"256","author":"Price","year":"1981","journal-title":"J Biol Chem"},{"issue":"6","key":"2023050817150009100_bnac031-B57","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1074\/mcp.M114.047621","article-title":"Gamma-carboxylation and fragmentation of osteocalcin in human serum defined by mass spectrometry","volume":"14","author":"Rehder","year":"2015","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"2023050817150009100_bnac031-B58","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/nu13020364","article-title":"Randomised controlled trial of nutritional supplement on bone turnover markers in Indian premenopausal women","volume":"13","author":"Umarji","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"2023050817150009100_bnac031-B59","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1210\/jc.2007-2490","article-title":"Effect of vitamin K supplementation on bone loss in elderly men and women","volume":"93","author":"Booth","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6590","key":"2023050817150009100_bnac031-B60","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/382448a0","article-title":"Increased bone formation in osteocalcin-deficient mice","volume":"382","author":"Ducy","year":"1996","journal-title":"Nature"},{"key":"2023050817150009100_bnac031-B61","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3389\/fendo.2018.00794","article-title":"Osteocalcin-a versatile bone-derived hormone","volume":"9","author":"Moser","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2023050817150009100_bnac031-B62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008714","article-title":"Osteocalcin promotes bone mineralization but is not a hormone","volume":"16","author":"Manolagas","year":"2020","journal-title":"PLoS Genet"},{"issue":"5","key":"2023050817150009100_bnac031-B63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008361","article-title":"An osteocalcin-deficient mouse strain without endocrine abnormalities","volume":"16","author":"Diegel","year":"2020","journal-title":"PLoS Genet"},{"issue":"12","key":"2023050817150009100_bnac031-B64","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.clinbiochem.2012.03.023","article-title":"Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum","volume":"45","author":"Koivula","year":"2012","journal-title":"Clin Biochem"},{"issue":"28","key":"2023050817150009100_bnac031-B65","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1016\/S0021-9258(19)76448-5","article-title":"The Mr 24,000 phosphoprotein from developing bone is the NH2-terminal propeptide of the a1 chain of type 1 collagen","volume":"262","author":"Fisher","year":"1987","journal-title":"J Biol Chem"},{"key":"2023050817150009100_bnac031-B66","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cca.2013.07.016","article-title":"Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters","volume":"425","author":"Cavalier","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"10","key":"2023050817150009100_bnac031-B67","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1515\/cclm-2019-0174","article-title":"A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism","volume":"57","author":"Cavalier","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"2023050817150009100_bnac031-B68","first-page":"333","article-title":"Molecular basis and clinical application of biological markers of bone turnover","volume":"17","author":"Calvo","year":"1996","journal-title":"Endocr Rev"},{"issue":"2","key":"2023050817150009100_bnac031-B69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1042\/bj2710345","article-title":"Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells","volume":"271","author":"Smedsr\u00f8d","year":"1990","journal-title":"Biochem J"},{"issue":"2","key":"2023050817150009100_bnac031-B70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1084\/jem.179.2.405","article-title":"Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells","volume":"179","author":"Melkko","year":"1994","journal-title":"J Exp Med"},{"issue":"12","key":"2023050817150009100_bnac031-B71","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1210\/jc.2015-2957","article-title":"Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women?","volume":"100","author":"Chavassieux","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B72","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00000658-199304000-00012","article-title":"Collagen synthesis in intact skin is suppressed during wound healing","volume":"217","author":"Ihlberg","year":"1993","journal-title":"Ann Surg"},{"issue":"1","key":"2023050817150009100_bnac031-B73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1183\/09031936.98.11010139","article-title":"Effects of long-term inhaled corticosteroids on skin collagen synthesis and thickness in asthmatic patients","volume":"11","author":"Haapasaari","year":"1998","journal-title":"Eur Respir J"},{"issue":"4","key":"2023050817150009100_bnac031-B74","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1359\/jbmr.1998.13.4.731","article-title":"Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis","volume":"13","author":"Gua\u00f1abens","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023050817150009100_bnac031-B75","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0950-3579(97)80018-0","article-title":"Bone markers","volume":"11","author":"Garnero","year":"1997","journal-title":"Baillieres Clin Rheumatol"},{"issue":"15","key":"2023050817150009100_bnac031-B76","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1074\/jbc.272.15.9755","article-title":"Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region","volume":"272","author":"Fledelius","year":"1997","journal-title":"J Biol Chem"},{"issue":"Pt 3","key":"2023050817150009100_bnac031-B77","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1042\/bj3450481","article-title":"Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover","volume":"345","author":"Gineyts","year":"2000","journal-title":"Biochem J"},{"issue":"9","key":"2023050817150009100_bnac031-B78","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1359\/jbmr.1997.12.9.1407","article-title":"Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget\u2019s disease of bone","volume":"12","author":"Garnero","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023050817150009100_bnac031-B79","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"Br J Cancer"},{"issue":"7","key":"2023050817150009100_bnac031-B80","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0009-9120(01)00269-7","article-title":"Variability in urinary excretion of bone resorption markers: limitations of a single determination in clinical practice","volume":"34","author":"Borderie","year":"2001","journal-title":"Clin Biochem"},{"issue":"3","key":"2023050817150009100_bnac031-B81","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1359\/jbmr.2000.15.3.594","article-title":"Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women","volume":"15","author":"Eastell","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023050817150009100_bnac031-B82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B83","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1359\/jbmr.1997.12.1.59","article-title":"Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis","volume":"12","author":"Eastell","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2023050817150009100_bnac031-B84","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B85","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1359\/jbmr.2003.18.4.658","article-title":"The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget\u2019s disease","volume":"18","author":"Naylor","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023050817150009100_bnac031-B86","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02556339","article-title":"Urinary beta-1-Galactosyl-O-Hydroxylysine (GH) as a marker of collagen turnover of bone","volume":"42","author":"Moro","year":"1988","journal-title":"Calcif Tiss Int"},{"issue":"5","key":"2023050817150009100_bnac031-B87","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/clinchem\/45.5.676","article-title":"Serum galactosyl hydroxylysine as a biochemical marker of bone resorption","volume":"45","author":"Al-Dehaimi","year":"1999","journal-title":"Clin Chem"},{"issue":"5","key":"2023050817150009100_bnac031-B88","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S8756-3282(00)00368-9","article-title":"Structure, function, and regulation of tartrate-resistant acid phosphatase","volume":"27","author":"Oddie","year":"2000","journal-title":"Bone"},{"issue":"6","key":"2023050817150009100_bnac031-B89","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00223-009-9309-8","article-title":"Biology and clinical significance of tartrate-resistant acid phosphatases: new perspectives on an old enzyme","volume":"85","author":"Janckila","year":"2009","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2023050817150009100_bnac031-B90","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ajcp\/104.4.397","article-title":"Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues","volume":"104","author":"Yaziji","year":"1995","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2023050817150009100_bnac031-B91","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1373\/clinchem.2003.029355","article-title":"Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis)","volume":"50","author":"Alatalo","year":"2004","journal-title":"Clin Chem"},{"issue":"10","key":"2023050817150009100_bnac031-B92","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1242\/dev.122.10.3151","article-title":"Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis","volume":"122","author":"Hayman","year":"1996","journal-title":"Development"},{"issue":"1","key":"2023050817150009100_bnac031-B93","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3892\/etm.2014.2071","article-title":"Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear kappaB ligand","volume":"9","author":"Lv","year":"2015","journal-title":"Exp Ther Med"},{"issue":"6","key":"2023050817150009100_bnac031-B94","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023050817150009100_bnac031-B95","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023050817150009100_bnac031-B96","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1359\/jbmr.091108","article-title":"Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment","volume":"25","author":"Moore","year":"2010","journal-title":"JBone Miner Res"},{"issue":"2","key":"2023050817150009100_bnac031-B97","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jbmr.5650030203","article-title":"Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females","volume":"3","author":"Recker","year":"1988","journal-title":"J Bone Miner Res"},{"key":"2023050817150009100_bnac031-B98","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bone.2018.03.019","article-title":"Bone histomorphometry in transiliac biopsies from 48 normal, healthy men","volume":"111","author":"Recker","year":"2018","journal-title":"Bone"},{"issue":"5","key":"2023050817150009100_bnac031-B99","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/ki.1988.96","article-title":"Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD","volume":"33","author":"Salusky","year":"1988","journal-title":"Kidney Int"},{"key":"2023050817150009100_bnac031-B100","doi-asserted-by":"crossref","DOI":"10.1159\/isbn.978-3-318-04339-6","volume-title":"Atlas of Mineralized Bone Histology","author":"Malluche","year":"1986"},{"issue":"1","key":"2023050817150009100_bnac031-B101","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-017-0550-5","article-title":"A comparative study of bone biopsies from the iliac crest, the tibial bone, and the lumbar spine","volume":"18","author":"Hiller","year":"2017","journal-title":"BMC Nephrol"},{"issue":"1","key":"2023050817150009100_bnac031-B102","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bone.2008.02.019","article-title":"Side-to-side and within-side variability of 3D bone microarchitecture by conventional micro-computed tomography of paired iliac crest biopsies","volume":"43","author":"Chappard","year":"2008","journal-title":"Bone"},{"issue":"5","key":"2023050817150009100_bnac031-B103","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00264-020-04492-2","article-title":"Burden of fractures in France: incidence and severity by age, gender, and site in 2016","volume":"44","author":"Bouyer","year":"2020","journal-title":"Int Orthop"},{"issue":"6","key":"2023050817150009100_bnac031-B104","first-page":"2264","article-title":"Changes in quantitative bone histomorphometry in aging healthy men","volume":"81","author":"Clarke","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023050817150009100_bnac031-B105","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1681\/ASN.2017050584","article-title":"Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy","volume":"29","author":"Salam","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2023050817150009100_bnac031-B106","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.ajkd.2021.07.027","article-title":"Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy","volume":"79","author":"Jorgensen","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2023050817150009100_bnac031-B107","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI112234","article-title":"Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion","volume":"76","author":"Charles","year":"1985","journal-title":"J Clin Invest"},{"issue":"4","key":"2023050817150009100_bnac031-B108","first-page":"296","article-title":"Age-related alterations in skeletal metabolism - 24 hour whole body retention of diphosphonate in 250 normal subjects: concise communication","volume":"23","author":"Fogelman","year":"1982","journal-title":"J Nucl Med"},{"issue":"3","key":"2023050817150009100_bnac031-B109","first-page":"338","article-title":"Quantitative studies of bone in postmenopausal women using (18)F-fluoride and (99 m)Tc-methylene diphosphonate","volume":"43","author":"Blake","year":"2002","journal-title":"J Nucl Med"},{"issue":"1","key":"2023050817150009100_bnac031-B110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/qims.2018.01.02","article-title":"Site specific measurements of bone formation using [(18)F] sodium fluoride PET\/CT","volume":"8","author":"Blake","year":"2018","journal-title":"Quant Imaging Med Surg"},{"key":"2023050817150009100_bnac031-B111","doi-asserted-by":"crossref","first-page":"115267","DOI":"10.1016\/j.bone.2020.115267","article-title":"Correlation between (18)F-Sodium Fluoride positron emission tomography and bone histomorphometry in dialysis patients","volume":"134","author":"Aaltonen","year":"2020","journal-title":"Bone"},{"key":"2023050817150009100_bnac031-B112","article-title":"Calcium isotope ratios in blood and urine: a new biomarker for the diagnosis of osteoporosis","volume":"10","author":"Eisenhauer","year":"2019","journal-title":"Bone Rep"},{"issue":"1","key":"2023050817150009100_bnac031-B113","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jbmr.4158","article-title":"Naturally occurring stable calcium isotope ratios in body compartments provide a novel biomarker of bone mineral balance in children and young adults","volume":"36","author":"Shroff","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023050817150009100_bnac031-B114","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/jclinpath-2014-202766","article-title":"Bone-specific alkaline phosphatase by immunoassay or electrophoresis: their use in clinical practice","volume":"68","author":"Ahmed","year":"2015","journal-title":"J Clin Pathol"},{"issue":"Pt 4","key":"2023050817150009100_bnac031-B115","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/000456329503200409","article-title":"Mass versus activity: validation of an immunometric assay for bone alkaline phosphatase in serum","volume":"32","author":"Price","year":"1995","journal-title":"Ann Clin Biochem"},{"issue":"9","key":"2023050817150009100_bnac031-B116","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/clinchem\/40.9.1749","article-title":"Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immunoradiometric assay","volume":"40","author":"Farley","year":"1994","journal-title":"Clin Chem"},{"issue":"1","key":"2023050817150009100_bnac031-B117","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0009-8981(75)90398-8","article-title":"A simplified heat-inactivation method for investigating alkaline phosphatase isoenzymes in serum","volume":"61","author":"Moss","year":"1975","journal-title":"Clin Chim Acta"},{"issue":"7","key":"2023050817150009100_bnac031-B118","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/clinchem\/30.7.1182","article-title":"Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma","volume":"30","author":"Rosalki","year":"1984","journal-title":"Clin Chem"},{"issue":"11","key":"2023050817150009100_bnac031-B119","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/clinchem\/41.11.1560","article-title":"Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum","volume":"41","author":"Gomez","year":"1995","journal-title":"Clin Chem"},{"issue":"2","key":"2023050817150009100_bnac031-B120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2265.1997.2221055.x","article-title":"Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis","volume":"47","author":"Takahashi","year":"1997","journal-title":"Clin Endocrinol"},{"issue":"13-14","key":"2023050817150009100_bnac031-B121","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.clinbiochem.2014.04.007","article-title":"Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients","volume":"47","author":"Cavalier","year":"2014","journal-title":"Clin Biochem"},{"issue":"2","key":"2023050817150009100_bnac031-B122","first-page":"178","article-title":"Comparison between bone alkaline phosphatase immunoassay and electrophoresis technique in hemodialysis patients","volume":"39","author":"Milinkovi\u0107","year":"2020","journal-title":"J Med Biochem"},{"issue":"5","key":"2023050817150009100_bnac031-B123","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00198-019-04837-7","article-title":"Bone turnover markers are differentially affected by pre-analytical handling","volume":"30","author":"Christensen","year":"2019","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B124","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1515\/CCLM.2010.019","article-title":"Analytical validation of serum bone alkaline phosphatase (BAP OSTASE) on Liaison","volume":"48","author":"Cavalier","year":"2010","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"2023050817150009100_bnac031-B125","first-page":"1046","article-title":"Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease","volume":"77","author":"Garnero","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023050817150009100_bnac031-B126","first-page":"91","article-title":"Evaluation of an immunoradiometric assay for bone alkaline phosphatase mass concentration in human sera","volume":"32","author":"Withold","year":"1994","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"Pt 4","key":"2023050817150009100_bnac031-B127","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/000456329303000403","article-title":"Multiple forms of human serum alkaline phosphatase: detection and quantitation","volume":"30","author":"Price","year":"1993","journal-title":"Ann Clin Biochem"},{"issue":"Pt 4","key":"2023050817150009100_bnac031-B128","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/000456320003700402","article-title":"Measurement of osteocalcin","volume":"37","author":"Lee","year":"2000","journal-title":"Ann Clin Biochem"},{"issue":"12","key":"2023050817150009100_bnac031-B129","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/jbmr.5650071206","article-title":"Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay","volume":"7","author":"Garnero","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2023050817150009100_bnac031-B130","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/clinchem\/41.10.1439","article-title":"Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies","volume":"41","author":"Rosenquist","year":"1995","journal-title":"Clin Chem"},{"issue":"1","key":"2023050817150009100_bnac031-B131","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1515\/CCLM.2004.017","article-title":"Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study)","volume":"42","author":"Schmidt-Gayk","year":"2004","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"2023050817150009100_bnac031-B132","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/0026-0495(88)90122-9","article-title":"Development of a new radioimmunoassay for human osteocalcin: evidence for a midmolecule epitope","volume":"37","author":"Taylor","year":"1988","journal-title":"Metabolism"},{"issue":"3","key":"2023050817150009100_bnac031-B133","first-page":"719","article-title":"Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study","volume":"82","author":"Vergnaud","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023050817150009100_bnac031-B134","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/jbmr.5650050506","article-title":"Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: a study of sources of variation in assay results","volume":"5","author":"Tracy","year":"1990","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023050817150009100_bnac031-B135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/clinchem\/41.2.318","article-title":"Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays","volume":"41","author":"Blumsohn","year":"1995","journal-title":"Clin Chem"},{"issue":"18","key":"2023050817150009100_bnac031-B136","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.clinbiochem.2010.09.019","article-title":"Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay","volume":"43","author":"Koivula","year":"2010","journal-title":"Clin Biochem"},{"issue":"1","key":"2023050817150009100_bnac031-B137","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1373\/clinchem.2007.094953","article-title":"Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis","volume":"54","author":"Garnero","year":"2008","journal-title":"Clin Chem"},{"issue":"2","key":"2023050817150009100_bnac031-B138","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/8756-3282(96)00165-2","article-title":"Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism","volume":"19","author":"Orum","year":"1996","journal-title":"Bone"},{"issue":"1","key":"2023050817150009100_bnac031-B139","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0028-2243(88)90167-0","article-title":"Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues","volume":"29","author":"Fay","year":"1988","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7-12","key":"2023050817150009100_bnac031-B140","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1699-0463.1992.tb04047.x","article-title":"Fetal antigen 2: an amniotic protein identified as the aminopropeptide of the alpha 1 chain of human procollagen type I","volume":"100","author":"Teisner","year":"1992","journal-title":"APMIS"},{"issue":"1","key":"2023050817150009100_bnac031-B141","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0009-9120(96)00134-8","article-title":"The aminoterminal propeptide of type I procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects","volume":"30","author":"T\u00e4htel\u00e4","year":"1997","journal-title":"Clin Biochem"},{"issue":"7","key":"2023050817150009100_bnac031-B142","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00198-017-4026-z","article-title":"Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population","volume":"28","author":"J\u00f8rgensen","year":"2017","journal-title":"Osteoporos Int"},{"issue":"10","key":"2023050817150009100_bnac031-B143","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1515\/cclm-2012-0531","article-title":"IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children","volume":"51","author":"Morovat","year":"2013","journal-title":"Clin Chem Lab Med"},{"issue":"7","key":"2023050817150009100_bnac031-B144","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1515\/cclm-2013-0934","article-title":"Method-specific differences in \u03b2-isomerised carboxy-terminal cross-linking telopeptide of type I collagen and procollagen type I amino-terminal propeptide using two fully automated immunoassays","volume":"52","author":"Wheater","year":"2014","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"2023050817150009100_bnac031-B145","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1359\/JBMR.041212","article-title":"Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget\u2019s disease of bone","volume":"20","author":"Alexandersen","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023050817150009100_bnac031-B146","first-page":"780","article-title":"Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023050817150009100_bnac031-B147","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","article-title":"Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen","volume":"44","author":"Rosenquist","year":"1998","journal-title":"Clin Chem"},{"issue":"8","key":"2023050817150009100_bnac031-B148","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/clinchem\/47.8.1410","article-title":"Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides","volume":"47","author":"Okabe","year":"2001","journal-title":"Clin Chem"},{"issue":"7-8","key":"2023050817150009100_bnac031-B149","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clinbiochem.2015.03.002","article-title":"Comparison of results from commercial assays for plasma CTX: The need for harmonization","volume":"48","author":"Chubb","year":"2015","journal-title":"Clin Biochem"},{"issue":"2","key":"2023050817150009100_bnac031-B150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1529-0131(199802)41:2<354::AID-ART20>3.0.CO;2-5","article-title":"Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget\u2019s disease","volume":"41","author":"Garnero","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2023050817150009100_bnac031-B151","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/clinchem\/42.10.1639","article-title":"Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption","volume":"42","author":"Bonde","year":"1996","journal-title":"Clin Chem"},{"issue":"11 Pt 1","key":"2023050817150009100_bnac031-B152","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/clinchem\/40.11.2022","article-title":"Immunoassay for quantifying type I collagen degradation products in urine evaluated","volume":"40","author":"Bonde","year":"1994","journal-title":"Clin Chem"},{"issue":"10","key":"2023050817150009100_bnac031-B153","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00198-012-2049-z","article-title":"National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges","volume":"23","author":"Bauer","year":"2012","journal-title":"Osteoporos Int"},{"issue":"6","key":"2023050817150009100_bnac031-B154","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00223-021-00816-5","article-title":"A multicenter study to evaluate harmonization of assays for C-terminal telopeptides of type I collagen (\u00df-CTX): a report from the IFCC-IOF Committee for Bone Metabolism (C-BM)","volume":"108","author":"Cavalier","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2023050817150009100_bnac031-B155","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/clinchem\/44.11.2290","article-title":"Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides","volume":"44","author":"Christgau","year":"1998","journal-title":"Clin Chem"},{"issue":"1-2","key":"2023050817150009100_bnac031-B156","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cccn.2004.07.024","article-title":"Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years","volume":"350","author":"Qvist","year":"2004","journal-title":"Clin Chim Acta"},{"issue":"7-8","key":"2023050817150009100_bnac031-B157","first-page":"455","article-title":"Influence of the sample matrix on the stability of beta-CTX at room temperature for 24 and 48 hours","volume":"53","author":"Lippi","year":"2007","journal-title":"Clin Lab"},{"issue":"1","key":"2023050817150009100_bnac031-B158","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1373\/clinchem.2010.157289","article-title":"The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism","volume":"57","author":"Stokes","year":"2011","journal-title":"Clin Chem"},{"issue":"11","key":"2023050817150009100_bnac031-B159","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/clinchem\/43.11.2058","article-title":"Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption","volume":"43","author":"Clemens","year":"1997","journal-title":"Clin Chem"},{"issue":"9","key":"2023050817150009100_bnac031-B160","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/clinchem\/43.9.1570","article-title":"Comparison of analytical performance and biological variability of three bone resorption assays","volume":"43","author":"Ju","year":"1997","journal-title":"Clin Chem"},{"issue":"3","key":"2023050817150009100_bnac031-B161","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00198-012-2097-4","article-title":"Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice","volume":"24","author":"Baxter","year":"2013","journal-title":"Osteoporos Int"},{"issue":"1-2","key":"2023050817150009100_bnac031-B162","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0009-8981(02)00208-5","article-title":"Instability and variability of urinary telopeptides and free crosslinks","volume":"324","author":"Schober","year":"2002","journal-title":"Clin Chim Acta"},{"issue":"4","key":"2023050817150009100_bnac031-B163","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/clinchem\/46.4.469","article-title":"Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum","volume":"46","author":"Nakanishi","year":"2000","journal-title":"Clin Chem"},{"issue":"4","key":"2023050817150009100_bnac031-B164","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/clinchem\/34.4.685","article-title":"Total, tartrate-resistant, and tartrate-inhibited acid phosphatases in serum: biological variations and reference limits","volume":"34","author":"Schiele","year":"1988","journal-title":"Clin Chem"},{"issue":"1","key":"2023050817150009100_bnac031-B165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/clinchem\/47.1.74","article-title":"Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity","volume":"47","author":"Janckila","year":"2001","journal-title":"Clin Chem"},{"issue":"5","key":"2023050817150009100_bnac031-B166","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jpba.2009.03.002","article-title":"Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay","volume":"49","author":"Wu","year":"2009","journal-title":"J Pharm Biomed Anal"},{"issue":"1-2","key":"2023050817150009100_bnac031-B167","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cca.2006.08.021","article-title":"Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b","volume":"376","author":"Ohashi","year":"2007","journal-title":"Clin Chim Acta"},{"issue":"3","key":"2023050817150009100_bnac031-B168","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1515\/cclm-2021-1190","article-title":"Analytical evaluation of the Nittobo Medical tartrate resistant acid phosphatase isoform 5b (TRACP-5b) EIA and comparison with IDS iSYS in different clinically defined populations","volume":"60","author":"Cavalier","year":"2021","journal-title":"Clin Chem Lab Med"},{"issue":"9-10","key":"2023050817150009100_bnac031-B169","first-page":"499","article-title":"Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption","volume":"52","author":"Halleen","year":"2006","journal-title":"Clin Lab"},{"issue":"3","key":"2023050817150009100_bnac031-B170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1359\/jbmr.080703","article-title":"Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States","volume":"24","author":"Glover","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"Suppl 6","key":"2023050817150009100_bnac031-B171","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","article-title":"Preanalytical variability of biochemical markers of bone turnover","volume":"11","author":"Hannon","year":"2000","journal-title":"Osteoporos Int"},{"issue":"7","key":"2023050817150009100_bnac031-B172","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1210\/jcem.87.7.8480","article-title":"Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors","volume":"87","author":"Finkelstein","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023050817150009100_bnac031-B173","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1373\/clinchem.2008.105866","article-title":"New automated multiplex assay for bone turnover markers in osteoporosis","volume":"54","author":"Claudon","year":"2008","journal-title":"Clin Chem"},{"issue":"5","key":"2023050817150009100_bnac031-B174","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-008-9126-5","article-title":"Determinants of bone turnover markers in healthy premenopausal women","volume":"82","author":"Adami","year":"2008","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2023050817150009100_bnac031-B175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1515\/cclm-2015-0162","article-title":"Reference intervals for bone turnover markers in Spanish premenopausal women","volume":"54","author":"Gua\u00f1abens","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"2023050817150009100_bnac031-B176","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bone.2012.02.003","article-title":"Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study","volume":"50","author":"Eastell","year":"2012","journal-title":"Bone"},{"issue":"5","key":"2023050817150009100_bnac031-B177","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bone.2007.01.008","article-title":"A cross-sectional study of bone turnover markers in healthy premenopausal women","volume":"40","author":"de Papp","year":"2007","journal-title":"Bone"},{"issue":"2","key":"2023050817150009100_bnac031-B178","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bone.2013.04.003","article-title":"Age-related reference intervals for bone turnover markers from an Australian reference population","volume":"55","author":"Jenkins","year":"2013","journal-title":"Bone"},{"issue":"1","key":"2023050817150009100_bnac031-B179","doi-asserted-by":"crossref","first-page":"43","DOI":"10.11005\/jbm.2020.27.1.43","article-title":"Reference intervals for bone turnover markers in Korean healthy women","volume":"27","author":"Cho","year":"2020","journal-title":"J Bone Metab"},{"key":"2023050817150009100_bnac031-B180","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/513925","article-title":"Establishing reference intervals for bone turnover markers in the healthy shanghai population and the relationship with bone mineral density in postmenopausal women","volume":"2013","author":"Hu","year":"2013","journal-title":"Int J Endocrinol"},{"issue":"4","key":"2023050817150009100_bnac031-B181","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bone.2010.07.017","article-title":"Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study","volume":"47","author":"Ardawi","year":"2010","journal-title":"Bone"},{"issue":"2","key":"2023050817150009100_bnac031-B182","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/jc.2006-1706","article-title":"Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years","volume":"92","author":"Rauchenzauner","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5-6","key":"2023050817150009100_bnac031-B183","first-page":"170","article-title":"A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults","volume":"57","author":"van der Sluis","year":"2002","journal-title":"Horm Res"},{"issue":"5","key":"2023050817150009100_bnac031-B184","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2265.1994.tb03019.x","article-title":"Biochemical markers of bone turnover in girls during puberty","volume":"40","author":"Blumsohn","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2023050817150009100_bnac031-B185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00198-019-05180-7","article-title":"Relationship between bone mineral content and bone turnover markers, sex hormones and calciotropic hormones in pre- and early pubertal children","volume":"31","author":"Z\u00fcrcher","year":"2020","journal-title":"Osteoporos Int"},{"issue":"3","key":"2023050817150009100_bnac031-B186","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2265.2009.03606.x","article-title":"Hormonal determinants of bone turnover before and after attainment of peak bone mass","volume":"72","author":"Walsh","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2023050817150009100_bnac031-B187","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1210\/jc.2012-1677","article-title":"Cortical consolidation of the radius and tibia in young men and women","volume":"97","author":"Walsh","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2023050817150009100_bnac031-B188","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2018.03.016","article-title":"Bone turnover markers after the menopause: T-score approach","volume":"111","author":"Gossiel","year":"2018","journal-title":"Bone"},{"issue":"7","key":"2023050817150009100_bnac031-B189","first-page":"2266","article-title":"Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen","volume":"83","author":"Khosla","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023050817150009100_bnac031-B190","first-page":"1522","article-title":"Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study","volume":"82","author":"Khosla","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B191","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S8756-3282(95)00243-X","article-title":"Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits","volume":"17","author":"Sone","year":"1995","journal-title":"Bone"},{"issue":"7","key":"2023050817150009100_bnac031-B192","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1359\/jbmr.1999.14.7.1203","article-title":"Age-related changes in bone turnover in men","volume":"14","author":"Fatayerji","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2023050817150009100_bnac031-B193","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s001980170034","article-title":"The Troms\u00f8 Study: a population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women","volume":"12","author":"Midtby","year":"2001","journal-title":"Osteoporos Int"},{"issue":"6","key":"2023050817150009100_bnac031-B194","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3109\/00365519009089183","article-title":"Plasma osteocalcin: biological variations and reference limits","volume":"50","author":"Tarallo","year":"1990","journal-title":"Scand J Clin Lab Invest"},{"issue":"6","key":"2023050817150009100_bnac031-B195","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s001980070094","article-title":"Ethnic and gender differences in bone mineral density and bone turnover in young adults: effect of bone size","volume":"11","author":"Henry","year":"2000","journal-title":"Osteoporos Int"},{"issue":"4","key":"2023050817150009100_bnac031-B196","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1359\/jbmr.1999.14.4.609","article-title":"Changes in bone resorption during the menstrual cycle","volume":"14","author":"Chiu","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023050817150009100_bnac031-B197","first-page":"388","article-title":"Possible variation in bone resorption during the normal menstrual cycle","volume":"129","author":"Schlemmer","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"4 Pt 1","key":"2023050817150009100_bnac031-B198","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/gme.0b013e31815f8917","article-title":"Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women","volume":"15","author":"Gass","year":"2008","journal-title":"Menopause"},{"issue":"5","key":"2023050817150009100_bnac031-B199","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1210\/jcem-70-5-1431","article-title":"Changes in biochemical markers of osteoblastic activity during the menstrual cycle","volume":"70","author":"Nielsen","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023050817150009100_bnac031-B200","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1210\/jcem.83.2.4584","article-title":"Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle","volume":"83","author":"Gorai","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B201","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00774-013-0430-4","article-title":"Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle","volume":"31","author":"Mozzanega","year":"2013","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2023050817150009100_bnac031-B202","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF00298428","article-title":"Urinary biochemical markers for bone resorption during the menstrual cycle","volume":"57","author":"Gorai","year":"1995","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2023050817150009100_bnac031-B203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1359\/jbmr.2000.15.1.129","article-title":"The effect of pregnancy on bone density and bone turnover","volume":"15","author":"Naylor","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023050817150009100_bnac031-B204","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1359\/jbmr.2000.15.3.557","article-title":"A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy","volume":"15","author":"Black","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2023050817150009100_bnac031-B205","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1210\/jc.2006-2695","article-title":"Racial and ethnic differences in bone turnover markers in men","volume":"92","author":"Leder","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023050817150009100_bnac031-B206","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1359\/jbmr.070505","article-title":"Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women","volume":"22","author":"Ivaska","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023050817150009100_bnac031-B207","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00198-005-2025-y","article-title":"Changes in bone mass and bone turnover following tibial shaft fracture","volume":"17","author":"Veitch","year":"2006","journal-title":"Osteoporos Int"},{"issue":"5","key":"2023050817150009100_bnac031-B208","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s001980050246","article-title":"Changes in bone mass and bone turnover following distal forearm fracture","volume":"10","author":"Ingle","year":"1999","journal-title":"Osteoporos Int"},{"issue":"5","key":"2023050817150009100_bnac031-B209","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s001980050247","article-title":"Changes in bone mass and bone turnover following ankle fracture","volume":"10","author":"Ingle","year":"1999","journal-title":"Osteoporos Int"},{"issue":"7","key":"2023050817150009100_bnac031-B210","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1046\/j.1532-5415.2001.49177.x","article-title":"Serum and urine markers of bone metabolism during the year after hip fracture","volume":"49","author":"Yu-Yahiro","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2023050817150009100_bnac031-B211","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00198-012-1920-2","article-title":"Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study","volume":"24","author":"Bhattoa","year":"2013","journal-title":"Osteoporos Int"},{"issue":"5","key":"2023050817150009100_bnac031-B212","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1359\/jbmr.040125","article-title":"Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study","volume":"19","author":"Pasco","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023050817150009100_bnac031-B213","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF02565126","article-title":"Seasonal variation in bone metabolism in young healthy subjects","volume":"49","author":"Vanderschueren","year":"1991","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2023050817150009100_bnac031-B214","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00198-013-2493-4","article-title":"Greater seasonal cycling of 25-hydroxyvitamin D is associated with increased parathyroid hormone and bone resorption","volume":"25","author":"Darling","year":"2014","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B215","first-page":"68","article-title":"Seasonal variation of biochemical indexes of bone turnover: results of a population-based study","volume":"83","author":"Woitge","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023050817150009100_bnac031-B216","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1359\/jbmr.0301218","article-title":"Seasonal variation of bone turnover?","volume":"19","author":"Seibel","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2023050817150009100_bnac031-B217","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1359\/jbmr.2003.18.7.1274","article-title":"Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study","volume":"18","author":"Blumsohn","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2023050817150009100_bnac031-B218","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115766","article-title":"The effects of acute exercise on bone turnover markers in middle-aged and older adults: a systematic review","volume":"143","author":"Smith","year":"2021","journal-title":"Bone"},{"issue":"5","key":"2023050817150009100_bnac031-B219","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s002230010071","article-title":"Serum isoforms of bone alkaline phosphatase increase during physical exercise in women","volume":"66","author":"Rudberg","year":"2000","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2023050817150009100_bnac031-B220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/bjsm.2004.013151","article-title":"Response of bone metabolism related hormones to a single session of strenuous exercise in active elderly subjects","volume":"39","author":"Ma\u00efmoun","year":"2005","journal-title":"Br J Sports Med"},{"issue":"4","key":"2023050817150009100_bnac031-B221","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF02508639","article-title":"The effects of brisk walking on markers of bone and calcium metabolism in postmenopausal women","volume":"58","author":"Thorsen","year":"1996","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2023050817150009100_bnac031-B222","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12891-016-1109-5","article-title":"Direct effects of physical training on markers of bone metabolism and serum sclerostin concentrations in older adults with low bone mass","volume":"17","author":"Gombos","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"2023050817150009100_bnac031-B223","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","author":"Szulc","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B224","first-page":"399","article-title":"Markers of bone metabolism during 14 days of bed rest in young and older men","volume":"17","author":"Buehlmeier","year":"2017","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"10","key":"2023050817150009100_bnac031-B225","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1359\/jbmr.1998.13.10.1594","article-title":"The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects","volume":"13","author":"Zerwekh","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023050817150009100_bnac031-B226","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1210\/jc.2010-0067","article-title":"Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss","volume":"95","author":"Gaudio","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023050817150009100_bnac031-B227","first-page":"3584","article-title":"Collagen cross-link excretion during space flight and bed rest","volume":"83","author":"Smith","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023050817150009100_bnac031-B228","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/clinchem\/45.10.1858","article-title":"Diurnal rhythm of CrossLaps in human serum","volume":"45","author":"Wichers","year":"1999","journal-title":"Clin Chem"},{"issue":"8","key":"2023050817150009100_bnac031-B229","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1210\/jc.2016-1183","article-title":"Diurnal Rhythms of Bone Turnover Markers in Three Ethnic Groups","volume":"101","author":"Redmond","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023050817150009100_bnac031-B230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"issue":"5","key":"2023050817150009100_bnac031-B231","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s002239900256","article-title":"Diurnal variation of bone mineral turnover in elderly men and women","volume":"60","author":"Greenspan","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"2023050817150009100_bnac031-B232","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bone.2018.10.002","article-title":"The 24-hour serum profiles of bone markers in healthy older men and women","volume":"120","author":"van der Spoel","year":"2019","journal-title":"Bone"},{"issue":"3","key":"2023050817150009100_bnac031-B233","first-page":"751","article-title":"Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women","volume":"83","author":"Heshmati","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023050817150009100_bnac031-B234","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S8756-3282(97)00039-2","article-title":"Circadian variation in bone resorption is not related to serum cortisol","volume":"21","author":"Schlemmer","year":"1997","journal-title":"Bone"},{"issue":"6","key":"2023050817150009100_bnac031-B235","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S8756-3282(02)00728-7","article-title":"Effect of feeding on bone turnover markers and its impact on biological variability of measurements","volume":"30","author":"Clowes","year":"2002","journal-title":"Bone"},{"issue":"11","key":"2023050817150009100_bnac031-B236","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1007\/s00198-017-4162-5","article-title":"24-hour profile of serum sclerostin and its association with bone biomarkers in men","volume":"28","author":"Swanson","year":"2017","journal-title":"Osteoporos Int"},{"issue":"12","key":"2023050817150009100_bnac031-B237","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00198-019-05135-y","article-title":"Rapid suppression of bone formation marker in response to sleep restriction and circadian disruption in men","volume":"30","author":"Swanson","year":"2019","journal-title":"Osteoporos Int"},{"issue":"7","key":"2023050817150009100_bnac031-B238","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1210\/clinem\/dgaa232","article-title":"Sleep restriction with circadian disruption negatively alter bone turnover markers in women","volume":"105","author":"Swanson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023050817150009100_bnac031-B239","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00198-022-06311-3","article-title":"The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis","volume":"33","author":"Gossiel","year":"2022","journal-title":"Osteoporos Int"},{"issue":"5","key":"2023050817150009100_bnac031-B240","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","article-title":"Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy","volume":"26","author":"Christgau","year":"2000","journal-title":"Bone"},{"issue":"1","key":"2023050817150009100_bnac031-B241","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S8756-3282(01)00662-7","article-title":"Mechanism of circadian variation in bone resorption","volume":"30","author":"Bjarnason","year":"2002","journal-title":"Bone"},{"issue":"12","key":"2023050817150009100_bnac031-B242","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1359\/jbmr.2003.18.12.2180","article-title":"Role of gastrointestinal hormones in postprandial reduction of bone resorption","volume":"18","author":"Henriksen","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023050817150009100_bnac031-B243","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bone.2006.09.025","article-title":"Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women","volume":"40","author":"Henriksen","year":"2007","journal-title":"Bone"},{"issue":"10","key":"2023050817150009100_bnac031-B244","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1210\/jc.2002-021447","article-title":"Octreotide abolishes the acute decrease in bone turnover in response to oral glucose","volume":"88","author":"Clowes","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023050817150009100_bnac031-B245","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00198-010-1513-x","article-title":"Effects of calcium-fortified ice cream on markers of bone health","volume":"22","author":"Ferrar","year":"2011","journal-title":"Osteoporos Int"},{"issue":"10","key":"2023050817150009100_bnac031-B246","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/ejcn.2016.42","article-title":"Food fortification for bone health in adulthood: a scoping review","volume":"70","author":"Whiting","year":"2016","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"2023050817150009100_bnac031-B247","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1017\/S0007114599001488","article-title":"No effect of copper supplementation on biochemical markers of bone metabolism in healthy adults","volume":"82","author":"Baker","year":"1999","journal-title":"Br J Nutr"},{"issue":"4","key":"2023050817150009100_bnac031-B248","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.ejcn.1600714","article-title":"The effect of magnesium supplementation on biochemical markers of bone metabolism or blood pressure in healthy young adult females","volume":"53","author":"Doyle","year":"1999","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"2023050817150009100_bnac031-B249","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-013-2402-x","article-title":"Effect of increased fruit and vegetable consumption on bone turnover in older adults: a randomised controlled trial","volume":"25","author":"Neville","year":"2014","journal-title":"Osteoporos Int"},{"issue":"7","key":"2023050817150009100_bnac031-B250","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/s41430-017-0081-y","article-title":"Bone turnover, calcium homeostasis, and vitamin D status in Danish vegans","volume":"72","author":"Hansen","year":"2018","journal-title":"Eur J Clin Nutr"},{"issue":"2","key":"2023050817150009100_bnac031-B251","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/nu10020183","article-title":"The assessment of bone regulatory pathways, bone turnover, and bone mineral density in vegetarian and omnivorous children","volume":"10","author":"Ambroszkiewicz","year":"2018","journal-title":"Nutrients"},{"issue":"9","key":"2023050817150009100_bnac031-B252","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s00198-006-0134-x","article-title":"The effect of a low-carbohydrate diet on bone turnover","volume":"17","author":"Carter","year":"2006","journal-title":"Osteoporos Int"},{"issue":"8","key":"2023050817150009100_bnac031-B253","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1017\/S0007114509371731","article-title":"The effects of a low-sodium base-producing diet including red meat compared with a high-carbohydrate, low-fat diet on bone turnover markers in women aged 45-75 years","volume":"102","author":"Nowson","year":"2009","journal-title":"Br J Nutr"},{"issue":"5","key":"2023050817150009100_bnac031-B254","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2265.2009.03688.x","article-title":"The effects of hormonal contraceptives on bone turnover markers and bone health","volume":"72","author":"Herrmann","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2023050817150009100_bnac031-B255","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/8756-3282(95)00075-O","article-title":"Decreased bone turnover in oral contraceptive users","volume":"16","author":"Garnero","year":"1995","journal-title":"Bone"},{"issue":"4","key":"2023050817150009100_bnac031-B256","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.contraception.2004.04.004","article-title":"Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women","volume":"70","author":"Paoletti","year":"2004","journal-title":"Contraception"},{"issue":"1","key":"2023050817150009100_bnac031-B257","first-page":"179","article-title":"Effects of contraceptive use on bone biochemical markers in young women","volume":"86","author":"Ott","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B258","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.contraception.2006.04.003","article-title":"Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling","volume":"74","author":"Shaarawy","year":"2006","journal-title":"Contraception"},{"issue":"4","key":"2023050817150009100_bnac031-B259","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1210\/jc.2007-2201","article-title":"Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study","volume":"93","author":"Walsh","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023050817150009100_bnac031-B260","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/157488608785699405","article-title":"Changes in bone turnover, bone mineral and fracture risk induced by drugs used to treat epilepsy","volume":"3","author":"Vestergaard","year":"2008","journal-title":"Curr Drug Saf"},{"issue":"2","key":"2023050817150009100_bnac031-B261","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00198-006-0185-z","article-title":"Anti-epileptic medication and bone health","volume":"18","author":"Petty","year":"2007","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B262","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clineuro.2009.10.011","article-title":"Bone and calcium metabolism and antiepileptic drugs","volume":"112","author":"Verrotti","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"2023050817150009100_bnac031-B263","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ana.20378","article-title":"Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy","volume":"57","author":"Pack","year":"2005","journal-title":"Ann Neurol"},{"issue":"2","key":"2023050817150009100_bnac031-B264","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1172\/JCI109142","article-title":"Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro","volume":"62","author":"Hahn","year":"1978","journal-title":"J Clin Invest"},{"issue":"3","key":"2023050817150009100_bnac031-B265","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1590\/S0004-27302007000300016","article-title":"Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapy","volume":"51","author":"Kulak","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"10","key":"2023050817150009100_bnac031-B266","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/j.1528-1167.2011.03131.x","article-title":"The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy","volume":"52","author":"Heo","year":"2011","journal-title":"Epilepsia"},{"issue":"1-5","key":"2023050817150009100_bnac031-B267","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jsbmb.2005.04.009","article-title":"Long-term effects of aromatase inhibitors on bone","volume":"95","author":"Eastell","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"2023050817150009100_bnac031-B268","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses","volume":"98","author":"Baum","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"2023050817150009100_bnac031-B269","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2023050817150009100_bnac031-B270","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023050817150009100_bnac031-B271","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2023050817150009100_bnac031-B272","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1158\/1078-0432.CCR-03-0735","article-title":"Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer","volume":"10","author":"Michaelson","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023050817150009100_bnac031-B273","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/EJE-20-0348","article-title":"Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study","volume":"183","author":"Khalil","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2023050817150009100_bnac031-B274","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1359\/jbmr.2000.15.7.1398","article-title":"Biochemical markers as predictors of rates of bone loss after menopause","volume":"15","author":"Rogers","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2023050817150009100_bnac031-B275","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1359\/jbmr.1999.14.8.1404","article-title":"Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures","volume":"14","author":"Bauer","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2023050817150009100_bnac031-B276","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s00198-016-3675-7","article-title":"Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study","volume":"27","author":"Marques","year":"2016","journal-title":"Osteoporos Int"},{"issue":"9","key":"2023050817150009100_bnac031-B277","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1359\/jbmr.1999.14.9.1614","article-title":"Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study","volume":"14","author":"Garnero","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023050817150009100_bnac031-B278","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jbspin.2011.05.004","article-title":"Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis","volume":"79","author":"Chopin","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"12","key":"2023050817150009100_bnac031-B279","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","article-title":"Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis","volume":"19","author":"Szulc","year":"2008","journal-title":"OsteoporosInt"},{"issue":"7","key":"2023050817150009100_bnac031-B280","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1210\/jc.2007-1508","article-title":"Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk","volume":"93","author":"Ivaska","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8542","key":"2023050817150009100_bnac031-B281","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(87)91671-0","article-title":"Prediction of rapid bone loss in postmenopausal women","volume":"1","author":"Christiansen","year":"1987","journal-title":"Lancet"},{"issue":"2","key":"2023050817150009100_bnac031-B282","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1359\/jbmr.1998.13.2.297","article-title":"Rapid bone loss is associated with increased levels of biochemical markers","volume":"13","author":"Ross","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2023050817150009100_bnac031-B283","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1210\/jc.2015-4262","article-title":"Quantifying the balance between total bone formation and total bone resorption: an index of net bone formation","volume":"101","author":"Shieh","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2023050817150009100_bnac031-B284","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1359\/jbmr.090526","article-title":"Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study","volume":"24","author":"Bauer","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023050817150009100_bnac031-B285","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jocd.2017.06.020","article-title":"Bone turnover markers: use in fracture prediction","volume":"20","author":"Vilaca","year":"2017","journal-title":"J Clin Densitom"},{"issue":"10","key":"2023050817150009100_bnac031-B286","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023050817150009100_bnac031-B287","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S8756-3282(00)00325-2","article-title":"Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study","volume":"27","author":"Chapurlat","year":"2000","journal-title":"Bone"},{"issue":"12","key":"2023050817150009100_bnac031-B288","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1359\/jbmr.2000.15.12.2473","article-title":"Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin","volume":"15","author":"Luukinen","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023050817150009100_bnac031-B289","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","article-title":"A meta-analysis of reference markers of bone turnover for prediction of fracture","volume":"94","author":"Johansson","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2023050817150009100_bnac031-B290","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13018-019-1100-6","article-title":"Reference markers of bone turnover for prediction of fracture: a meta-analysis","volume":"14","author":"Tian","year":"2019","journal-title":"J Orthop Surg Res"},{"issue":"3","key":"2023050817150009100_bnac031-B291","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jocd.2011.05.008","article-title":"Official Positions for FRAX(R) clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R)","volume":"14","author":"McCloskey","year":"2011","journal-title":"J Clin Densitom"},{"issue":"2","key":"2023050817150009100_bnac031-B292","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial","volume":"21","author":"Bauer","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023050817150009100_bnac031-B293","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","article-title":"Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2023050817150009100_bnac031-B294","doi-asserted-by":"crossref","DOI":"10.1016\/j.bonr.2020.100275","article-title":"Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial","volume":"12","author":"Mawatari","year":"2020","journal-title":"Bone Reports"},{"issue":"1","key":"2023050817150009100_bnac031-B295","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00774-018-0931-2","article-title":"Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis","volume":"37","author":"Okazaki","year":"2019","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"2023050817150009100_bnac031-B296","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jbmr.2361","article-title":"Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study","volume":"30","author":"Eastell","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2023050817150009100_bnac031-B297","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023050817150009100_bnac031-B298","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s001980070111","article-title":"Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"11","author":"Lane","year":"2000","journal-title":"Osteoporos Int"},{"issue":"2","key":"2023050817150009100_bnac031-B299","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00774-012-0403-z","article-title":"Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 \u03bcg\/day administered subcutaneously in Japanese patients with osteoporosis","volume":"31","author":"Yamamoto","year":"2013","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2023050817150009100_bnac031-B300","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","article-title":"Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover","volume":"39","author":"Delmas","year":"2006","journal-title":"Bone"},{"issue":"4","key":"2023050817150009100_bnac031-B301","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jbmr.3355","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression","volume":"33","author":"Bauer","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023050817150009100_bnac031-B302","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023050817150009100_bnac031-B303","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023050817150009100_bnac031-B304","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","author":"Diez-Perez","year":"2017","journal-title":"Osteoporos Int"},{"issue":"2","key":"2023050817150009100_bnac031-B305","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1373\/clinchem.2010.148841","article-title":"Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care","volume":"57","author":"Little","year":"2011","journal-title":"Clin Chem"},{"issue":"1","key":"2023050817150009100_bnac031-B306","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/EJE-17-0585","article-title":"DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?","volume":"178","author":"Eastell","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023050817150009100_bnac031-B307","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B308","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023050817150009100_bnac031-B309","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-011-1583-4","article-title":"Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"issue":"5","key":"2023050817150009100_bnac031-B310","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2023050817150009100_bnac031-B311","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/ard.62.10.969","article-title":"Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women","volume":"62","author":"Stakkestad","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2023050817150009100_bnac031-B312","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children","volume":"10","author":"Papapoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"2023050817150009100_bnac031-B313","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bone.2011.06.027","article-title":"Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover","volume":"49","author":"Peris","year":"2011","journal-title":"Bone"},{"issue":"7","key":"2023050817150009100_bnac031-B314","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: a population-based cohort study","volume":"33","author":"Adams","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2023050817150009100_bnac031-B315","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2023050817150009100_bnac031-B316","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch Osteoporos"},{"issue":"6","key":"2023050817150009100_bnac031-B317","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/jbmr.1864","article-title":"BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate","volume":"28","author":"McNabb","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023050817150009100_bnac031-B318","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00198-018-04823-5","article-title":"Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis","volume":"30","author":"Naylor","year":"2019","journal-title":"Osteoporos Int"},{"issue":"5","key":"2023050817150009100_bnac031-B319","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jbmr.3654","article-title":"Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension I trials","volume":"34","author":"Kim","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2023050817150009100_bnac031-B320","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","article-title":"Five years of anti-resorptive activity after a single dose of zoledronate\u2014results from a randomized double-blind placebo-controlled trial","volume":"50","author":"Grey","year":"2012","journal-title":"Bone"},{"issue":"25","key":"2023050817150009100_bnac031-B321","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2023050817150009100_bnac031-B322","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2023050817150009100_bnac031-B323","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diab Endocrinol"},{"issue":"1","key":"2023050817150009100_bnac031-B324","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2023050817150009100_bnac031-B325","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"issue":"8","key":"2023050817150009100_bnac031-B326","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023050817150009100_bnac031-B327","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"2023050817150009100_bnac031-B328","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023050817150009100_bnac031-B329","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B330","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","article-title":"Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates","volume":"103","author":"Tripto-Shkolnik","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2023050817150009100_bnac031-B331","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"4","key":"2023050817150009100_bnac031-B332","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2023050817150009100_bnac031-B333","first-page":"1","article-title":"Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation","volume":"2018","author":"Gonzalez-Rodriguez","year":"2018","journal-title":"Case Rep Rheumatol"},{"issue":"3","key":"2023050817150009100_bnac031-B334","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023050817150009100_bnac031-B335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bonr.2020.100290","article-title":"Effect of risedronate on bone loss at discontinuation of denosumab","volume":"13","author":"Laroche","year":"2020","journal-title":"Bone Reports"},{"issue":"12","key":"2023050817150009100_bnac031-B336","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023050817150009100_bnac031-B337","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"2023050817150009100_bnac031-B338","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2023050817150009100_bnac031-B339","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"S\u00f8lling","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2023050817150009100_bnac031-B340","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023050817150009100_bnac031-B341","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"2023050817150009100_bnac031-B342","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos Int"},{"issue":"4","key":"2023050817150009100_bnac031-B343","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2796.2004.01317.x","article-title":"Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAXR versus EVISTARComparison Trial) International","volume":"255","author":"Sambrook","year":"2004","journal-title":"J Intern Med"},{"issue":"8","key":"2023050817150009100_bnac031-B344","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s00198-016-3573-z","article-title":"Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"issue":"11","key":"2023050817150009100_bnac031-B345","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00198-013-2386-6","article-title":"Adherence to raloxifene therapy: assessment methods and relationship with efficacy","volume":"24","author":"Finigan","year":"2013","journal-title":"Osteoporos Int"},{"issue":"926","key":"2023050817150009100_bnac031-B346","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/pmj.78.926.727","article-title":"Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women","volume":"78","author":"Dogan","year":"2002","journal-title":"Postgrad Med J"},{"issue":"3","key":"2023050817150009100_bnac031-B347","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S8756-3282(99)00175-1","article-title":"Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy","volume":"25","author":"Peris","year":"1999","journal-title":"Bone"},{"issue":"6","key":"2023050817150009100_bnac031-B348","first-page":"1904","article-title":"The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation","volume":"82","author":"Rosen","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023050817150009100_bnac031-B349","first-page":"2419","article-title":"Tibolone: prevention of bone loss in late postmenopausal women","volume":"81","author":"Bjarnason","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023050817150009100_bnac031-B350","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","author":"Eastell","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2023050817150009100_bnac031-B351","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2010.12.006","article-title":"PINP as an aid for monitoring patients treated with teriparatide","volume":"48","author":"Tsujimoto","year":"2011","journal-title":"Bone"},{"issue":"9","key":"2023050817150009100_bnac031-B352","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00198-014-2646-0","article-title":"PINP as a biological response marker during teriparatide treatment for osteoporosis","volume":"25","author":"Krege","year":"2014","journal-title":"Osteoporos Int"},{"issue":"2","key":"2023050817150009100_bnac031-B353","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"16","key":"2023050817150009100_bnac031-B354","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2023050817150009100_bnac031-B355","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2023050817150009100_bnac031-B356","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B357","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1210\/clinem\/dgaa084","article-title":"Normocalcemic hyperparathyroidism: study of its prevalence and natural history","volume":"105","author":"Schini","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023050817150009100_bnac031-B358","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/8756-3282(95)80020-Q","article-title":"Reconstruction of cortical bone remodeling in untreated primary hyperparathyroidism and following surgery","volume":"16","author":"Brockstedt","year":"1995","journal-title":"Bone"},{"issue":"1","key":"2023050817150009100_bnac031-B359","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S8756-3282(97)00078-1","article-title":"Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients","volume":"21","author":"Christiansen","year":"1997","journal-title":"Bone"},{"issue":"7","key":"2023050817150009100_bnac031-B360","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/BF00311432","article-title":"Evaluation of bone loss and the serum markers of bone metabolism in patients with hyperparathyroidism","volume":"25","author":"Katagiri","year":"1995","journal-title":"Surg Today"},{"issue":"2","key":"2023050817150009100_bnac031-B361","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2796.1998.00241.x","article-title":"Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease","volume":"243","author":"Valdemarsson","year":"1998","journal-title":"J Intern Med"},{"issue":"10","key":"2023050817150009100_bnac031-B362","first-page":"3487","article-title":"Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"81","author":"Guo","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023050817150009100_bnac031-B363","first-page":"723","article-title":"Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism","volume":"80","author":"Silverberg","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2023050817150009100_bnac031-B364","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/128352","article-title":"Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone?","volume":"2012","author":"Amaral","year":"2012","journal-title":"J Osteoporos"},{"issue":"3","key":"2023050817150009100_bnac031-B365","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s12020-015-0611-0","article-title":"Polymorphisms of the vitamin D receptor and their effect on bone mass density in patients with normocalcemic hyperparathyroidism","volume":"50","author":"Castrillon","year":"2015","journal-title":"Endocrine"},{"issue":"3","key":"2023050817150009100_bnac031-B366","first-page":"163","article-title":"Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism","volume":"48","author":"Diaz-Soto","year":"2016","journal-title":"Horm Metab Res"},{"issue":"8","key":"2023050817150009100_bnac031-B367","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/jc.2013-1518","article-title":"Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism","volume":"98","author":"Koumakis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023050817150009100_bnac031-B368","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1590\/S0004-27302011000500003","article-title":"Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?","volume":"55","author":"Marques","year":"2011","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"7","key":"2023050817150009100_bnac031-B369","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1210\/jc.2013-1300","article-title":"Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023050817150009100_bnac031-B370","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1308\/rcsann.2017.0092","article-title":"Changes in bone turnover markers in primary hyperparathyroidism and response to surgery","volume":"99","author":"Rajeev","year":"2017","journal-title":"Ann R Coll Surg Engl"},{"issue":"2","key":"2023050817150009100_bnac031-B371","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(99)00150-7","article-title":"Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy","volume":"25","author":"Christiansen","year":"1999","journal-title":"Bone"},{"issue":"10","key":"2023050817150009100_bnac031-B372","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s40618-020-01269-7","article-title":"Biochemical bone turnover markers in hormonal disorders in adults: a narrative review","volume":"43","author":"Szulc","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2023050817150009100_bnac031-B373","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2265.2000.00900.x","article-title":"Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones","volume":"52","author":"Abe","year":"2000","journal-title":"Clin Endocrinol"},{"issue":"7","key":"2023050817150009100_bnac031-B374","first-page":"640","article-title":"The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy","volume":"35","author":"Alonso","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2023050817150009100_bnac031-B375","first-page":"394","article-title":"Prediction of bone mass changes after successful parathyroidectomy using biochemical markers of bone metabolism in primary hyperparathyroidism: is it clinically useful?","volume":"63","author":"Ohe","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B376","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/EJE-21-0322","article-title":"Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study","volume":"185","author":"Ryh\u00e4nen","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023050817150009100_bnac031-B377","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023050817150009100_bnac031-B378","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023050817150009100_bnac031-B379","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023050817150009100_bnac031-B380","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism","volume":"16","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2023050817150009100_bnac031-B381","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2001-010385","article-title":"Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study","volume":"87","author":"Parker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"2023050817150009100_bnac031-B382","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.160.14.2161","article-title":"Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women","volume":"160","author":"Orr-Walker","year":"2000","journal-title":"Arch Intern Med"},{"issue":"7","key":"2023050817150009100_bnac031-B383","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4158\/EP08178.ORR","article-title":"Alendronate therapy in men with primary hyperparathyroidism","volume":"15","author":"Khan","year":"2009","journal-title":"Endocr Pract"},{"issue":"4","key":"2023050817150009100_bnac031-B384","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2015","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B385","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023050817150009100_bnac031-B386","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"issue":"8","key":"2023050817150009100_bnac031-B387","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1-2","key":"2023050817150009100_bnac031-B388","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2005.12.031","article-title":"Bone resorption markers in vitamin D insufficiency","volume":"368","author":"Need","year":"2006","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2023050817150009100_bnac031-B389","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bone.2004.02.003","article-title":"The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis","volume":"35","author":"Sahota","year":"2004","journal-title":"Bone"},{"issue":"3","key":"2023050817150009100_bnac031-B390","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1210\/jcem.86.3.7327","article-title":"A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial","volume":"86","author":"Lips","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023050817150009100_bnac031-B391","first-page":"1146","article-title":"Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings","volume":"74","author":"Demiaux","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2023050817150009100_bnac031-B392","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJM199803193381201","article-title":"Hypovitaminosis D in medical inpatients","volume":"338","author":"Thomas","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"2023050817150009100_bnac031-B393","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2265.2007.03040.x","article-title":"Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality","volume":"68","author":"Chen","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023050817150009100_bnac031-B394","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bone.2019.04.002","article-title":"Effects of vitamin D supplementation on bone turnover markers and other bone-related substances in subjects with vitamin D deficiency","volume":"124","author":"Jorde","year":"2019","journal-title":"Bone"},{"issue":"4","key":"2023050817150009100_bnac031-B395","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00774-018-0957-5","article-title":"Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy","volume":"37","author":"McKenna","year":"2019","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"2023050817150009100_bnac031-B396","first-page":"879","article-title":"A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets","volume":"75","author":"Sullivan","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023050817150009100_bnac031-B397","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023050817150009100_bnac031-B398","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00223-009-9275-1","article-title":"Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases","volume":"85","author":"Rendina","year":"2009","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2023050817150009100_bnac031-B399","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/jbmr.4325","article-title":"Impaired bone microarchitecture and strength in patients with tumor-induced osteomalacia","volume":"36","author":"Zanchetta","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2023050817150009100_bnac031-B400","article-title":"High bone turnover and hyperparathyroidism after surgery for tumor-induced osteomalacia: A case series","volume":"15","author":"Kilbane","year":"2021","journal-title":"Bone Rep"},{"issue":"4","key":"2023050817150009100_bnac031-B401","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2023050817150009100_bnac031-B402","doi-asserted-by":"crossref","first-page":"568","DOI":"10.7861\/clinmed.20.6.page","article-title":"Adult Paget\u2019s disease of bone","volume":"20","author":"Tuck","year":"2020","journal-title":"Clin Med"},{"issue":"5","key":"2023050817150009100_bnac031-B403","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00223-014-9904-1","article-title":"Clinical presentation of Paget\u2019s disease: evaluation of a contemporary cohort and systematic review","volume":"95","author":"Tan","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2023050817150009100_bnac031-B404","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00198-015-3095-0","article-title":"Bone turnover markers in Paget\u2019s disease of the bone: a systematic review and meta-analysis","volume":"26","author":"Al Nofal","year":"2015","journal-title":"Osteoporos Int"},{"issue":"8","key":"2023050817150009100_bnac031-B405","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jbmr.5650110817","article-title":"Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links","volume":"11","author":"Randall","year":"1996","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023050817150009100_bnac031-B406","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00223-005-0247-9","article-title":"Biochemical response to bisphosphonate therapy in Pagetic patients with skull involvement","volume":"79","author":"Peris","year":"2006","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2023050817150009100_bnac031-B407","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jbmr.3657","article-title":"Diagnosis and management of Paget\u2019s disease of bone in adults: a clinical guideline","volume":"34","author":"Ralston","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2023050817150009100_bnac031-B408","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bone.2018.06.011","article-title":"Clinical utility of bone markers in various diseases","volume":"114","author":"Vlot","year":"2018","journal-title":"Bone"},{"issue":"1","key":"2023050817150009100_bnac031-B409","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","article-title":"Comparative responses of bone turnover markers to bisphosphonate therapy in Paget\u2019s disease of bone","volume":"35","author":"Reid","year":"2004","journal-title":"Bone"},{"issue":"5","key":"2023050817150009100_bnac031-B410","first-page":"1810","article-title":"Paget\u2019s disease is associated with changes in the immunohistochemical distribution of noncollagenous matrix proteins in bone","volume":"81","author":"Ingram","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B411","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1359\/JBMR.041212","article-title":"Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget\u2019s disease of bone","volume":"20","author":"Alexandersen","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"2023050817150009100_bnac031-B412","doi-asserted-by":"crossref","first-page":"P92","DOI":"10.1359\/jbmr.06s217","article-title":"Guidelines for the diagnosis and management of Paget\u2019s disease: a UK perspective","volume":"21","author":"Selby","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023050817150009100_bnac031-B413","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s00774-014-0623-5","article-title":"Clinical efficacy of oral risedronate therapy in Japanese patients with Paget\u2019s disease of bone","volume":"33","author":"Ohara","year":"2015","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2023050817150009100_bnac031-B414","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous Dysplasia\/McCune-Albright syndrome: a rare, mosaic disease of G\u03b1\u200a activation","volume":"41","author":"Boyce","year":"2020","journal-title":"Endocr Rev"},{"issue":"2","key":"2023050817150009100_bnac031-B415","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/berh.1999.0071","article-title":"Fibrous dysplasia of bone","volume":"14","author":"Chapurlat","year":"2000","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"2023050817150009100_bnac031-B416","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone","volume":"34","author":"Florenzano","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2023050817150009100_bnac031-B417","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.archoralbio.2018.05.018","article-title":"Direct evidence for the age-dependent demise of GNAS-mutated cells in oral fibrous dysplasia","volume":"93","author":"Isobe","year":"2018","journal-title":"Arch Oral Biol"},{"issue":"11","key":"2023050817150009100_bnac031-B418","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1359\/jbmr.080609","article-title":"Age-dependent demise of GNAS-mutated skeletal stem cells and \u201cnormalization\u201d of fibrous dysplasia of bone","volume":"23","author":"Kuznetsov","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2023050817150009100_bnac031-B419","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023050817150009100_bnac031-B420","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1210\/jc.2003-030050","article-title":"Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone","volume":"88","author":"Plotkin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023050817150009100_bnac031-B421","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00256-017-2698-2","article-title":"Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune\u2013Albright syndrome","volume":"46","author":"Corsi","year":"2017","journal-title":"Skeletal Radiol"},{"issue":"10","key":"2023050817150009100_bnac031-B422","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.joms.2016.04.001","article-title":"Fibrous dysplasia and medication-related osteonecrosis of the jaw","volume":"74","author":"Metwally","year":"2016","journal-title":"J Oral Maxillofacial Surg"},{"issue":"3","key":"2023050817150009100_bnac031-B423","first-page":"253","article-title":"Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia","volume":"13","author":"Eller-Vainicher","year":"2016","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"2","key":"2023050817150009100_bnac031-B424","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00198-013-2585-1","article-title":"Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases","volume":"25","author":"Ganda","year":"2014","journal-title":"Osteoporos Int"},{"issue":"6","key":"2023050817150009100_bnac031-B425","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jbspin.2014.04.013","article-title":"Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment","volume":"81","author":"Benhamou","year":"2014","journal-title":"Joint Bone Spine"},{"key":"2023050817150009100_bnac031-B426","author":"Clinicaltrials.gov"},{"key":"2023050817150009100_bnac031-B427","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115577","article-title":"Establishing race-, gender- and age-specific reference intervals for pyridoxal 5\u2032-phosphate in the NHANES population to better identify adult hypophosphatasia","volume":"141","author":"Schini","year":"2020","journal-title":"Bone"},{"key":"2023050817150009100_bnac031-B428","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115795","article-title":"Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic","volume":"144","author":"Desborough","year":"2021","journal-title":"Bone"},{"key":"2023050817150009100_bnac031-B429","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","article-title":"Hypophosphatasia: an overview For 2017","volume":"102","author":"Whyte","year":"2017","journal-title":"Bone"},{"issue":"4","key":"2023050817150009100_bnac031-B430","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/clinchem\/41.4.515","article-title":"Significance of low serum alkaline phosphatase activity in a predominantly adult male population","volume":"41","author":"Lum","year":"1995","journal-title":"Clin Chem"},{"issue":"9","key":"2023050817150009100_bnac031-B431","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00198-018-4571-0","article-title":"Abnormal bone turnover in individuals with low serum alkaline phosphatase","volume":"29","author":"L\u00f3pez-Delgado","year":"2018","journal-title":"Osteoporos Int"},{"issue":"12","key":"2023050817150009100_bnac031-B432","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s00198-021-06025-y","article-title":"Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos Int"},{"issue":"8","key":"2023050817150009100_bnac031-B433","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"9","key":"2023050817150009100_bnac031-B434","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","volume":"23","author":"Lekamwasam","year":"2012","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B435","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jbmr.5650030117","article-title":"Effect of short-term glucocorticoids on serum osteocalcin in healthy young men","volume":"3","author":"Godschalk","year":"1988","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2023050817150009100_bnac031-B436","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/jbmr.5650090718","article-title":"High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton","volume":"9","author":"Cosman","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"4934","key":"2023050817150009100_bnac031-B437","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.2588000","article-title":"1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene","volume":"246","author":"Morrison","year":"1989","journal-title":"Science"},{"issue":"10","key":"2023050817150009100_bnac031-B438","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2222.1996.tb00508.x","article-title":"Effects of prednisolone on bone turnover in patients with corticosteroid resistant asthma","volume":"26","author":"Lane","year":"1996","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"2023050817150009100_bnac031-B439","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/thx.47.6.418","article-title":"Bone turnover during short course prednisolone treatment in patients with chronic obstructive airways disease","volume":"47","author":"Morrison","year":"1992","journal-title":"Thorax"},{"issue":"5","key":"2023050817150009100_bnac031-B440","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/ard.55.5.288","article-title":"Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis","volume":"55","author":"Lems","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2023050817150009100_bnac031-B441","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00223-012-9684-4","article-title":"Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes","volume":"92","author":"Brabnikova Maresova","year":"2013","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2023050817150009100_bnac031-B442","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1210\/jc.2003-022025","article-title":"11\u03b2-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone","volume":"88","author":"Cooper","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023050817150009100_bnac031-B443","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1530\/EC-19-0104","article-title":"Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans","volume":"8","author":"Thiele","year":"2019","journal-title":"Endocr Connect"},{"key":"2023050817150009100_bnac031-B444","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3389\/fmed.2020.00551","article-title":"Wnt inhibitors and bone turnover markers in patients with polymyalgia rheumatica and acute effects of glucocorticoid treatment","volume":"7","author":"Fassio","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"2023050817150009100_bnac031-B445","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1210\/jcem-72-2-382","article-title":"The course of biochemical parameters of bone turnover during treatment with corticosteroids","volume":"72","author":"Prummel","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023050817150009100_bnac031-B446","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002239900352","article-title":"Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients","volume":"61","author":"Gonnelli","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"2023050817150009100_bnac031-B447","doi-asserted-by":"crossref","first-page":"115457","DOI":"10.1016\/j.bone.2020.115457","article-title":"The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: a systematic review and meta-analysis update","volume":"137","author":"Vilaca","year":"2020","journal-title":"Bone"},{"issue":"4","key":"2023050817150009100_bnac031-B448","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2013a meta-analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos Int"},{"issue":"6","key":"2023050817150009100_bnac031-B449","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/jbmr.4271","article-title":"The effects of type 1 diabetes and diabetic peripheral neuropathy on the musculoskeletal system: a case-control study","volume":"36","author":"Vilaca","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2023050817150009100_bnac031-B450","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/jbmr.2573","article-title":"Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in adult patients with type 1 diabetes mellitus","volume":"30","author":"Shanbhogue","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023050817150009100_bnac031-B451","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/cen.14501","article-title":"Characteristics of bone metabolism in postmenopausal women with newly diagnosed type 2 diabetes mellitus","volume":"95","author":"Li","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2023050817150009100_bnac031-B452","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1530\/EJE-16-0652","article-title":"MECHANISMS IN ENDOCRINOLOGY: diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis","volume":"176","author":"Hygum","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023050817150009100_bnac031-B453","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00198-014-2676-7","article-title":"Biochemical markers of bone turnover in diabetes patients\u2013a meta-analysis, and a methodological study on the effects of glucose on bone markers","volume":"25","author":"Starup-Linde","year":"2014","journal-title":"Osteoporos Int"},{"issue":"4","key":"2023050817150009100_bnac031-B454","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1530\/EJE-11-1061","article-title":"Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus","volume":"166","author":"van Lierop","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023050817150009100_bnac031-B455","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF03345061","article-title":"Bone turnover in hyperthyroidism before and after thyrostatic management","volume":"23","author":"Isaia","year":"2000","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2023050817150009100_bnac031-B456","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2265.1999.00626.x","article-title":"Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time","volume":"50","author":"Olkawa","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023050817150009100_bnac031-B457","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1472-6823-11-15","article-title":"Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men","volume":"11","author":"El Hadidy el","year":"2011","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"2023050817150009100_bnac031-B458","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/cen.12560","article-title":"Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression","volume":"82","author":"Tournis","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2023050817150009100_bnac031-B459","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/105072503321669839","article-title":"Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment","volume":"13","author":"Mikosch","year":"2003","journal-title":"Thyroid"},{"issue":"1","key":"2023050817150009100_bnac031-B460","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1186\/s12891-020-03804-2","article-title":"Bone phenotypes in rheumatology - there is more to bone than just bone","volume":"21","author":"Thudium","year":"2020","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"2023050817150009100_bnac031-B461","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00198-018-4473-1","article-title":"Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"29","author":"Jin","year":"2018","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023050817150009100_bnac031-B462","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1749-6632.2002.tb04254.x","article-title":"Serum osteocalcin levels in premenopausal rheumatoid arthritis patients","volume":"966","author":"Seriolo","year":"2002","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"2023050817150009100_bnac031-B463","first-page":"1250","article-title":"Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis","volume":"26","author":"Al-Awadhi","year":"1999","journal-title":"J Rheumatol"},{"issue":"3","key":"2023050817150009100_bnac031-B464","first-page":"153","article-title":"How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy","volume":"64","author":"Cortet","year":"1997","journal-title":"Rev Rhum Engl Ed"},{"issue":"9-10","key":"2023050817150009100_bnac031-B465","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1445-5994.2004.00647.x","article-title":"Telopeptides as markers of bone turnover in rheumatoid arthritis and osteoarthritis","volume":"34","author":"Wong","year":"2004","journal-title":"Intern Med J"},{"issue":"12","key":"2023050817150009100_bnac031-B466","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00296-009-0867-x","article-title":"Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis","volume":"29","author":"Wis\u0142owska","year":"2009","journal-title":"Rheumatol Int"},{"issue":"11","key":"2023050817150009100_bnac031-B467","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/jbmr.2266","article-title":"Thalassemia bone disease: a 19 year longitudinal analysis","volume":"29","author":"Wong","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023050817150009100_bnac031-B468","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jbspin.2012.08.004","article-title":"Common bone turnover markers in rheumatoid arthritis and ankylosing spondylitis: a literature review","volume":"80","author":"Coiffier","year":"2013","journal-title":"Joint Bone Spine"},{"issue":"6","key":"2023050817150009100_bnac031-B469","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kei280","article-title":"The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis","volume":"45","author":"Torikai","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2023050817150009100_bnac031-B470","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.2007.076604","article-title":"Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis","volume":"67","author":"Chopin","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2023050817150009100_bnac031-B471","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10067-008-0870-8","article-title":"Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis","volume":"27","author":"Yasunori","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"4A","key":"2023050817150009100_bnac031-B472","first-page":"1961","article-title":"Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas","volume":"27","author":"Oremek","year":"2007","journal-title":"Anticancer Res"},{"issue":"12","key":"2023050817150009100_bnac031-B473","first-page":"5277","article-title":"Study on diagnostic value of P1NP and \u03b2-CTX in bone metastasis of patients with breast cancer and the correlation between them","volume":"23","author":"Zuo","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"2023050817150009100_bnac031-B474","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF02967492","article-title":"Evaluation of bone metabolic markers in breast cancer with bone metastasis","volume":"8","author":"Wada","year":"2001","journal-title":"Breast Cancer"},{"key":"2023050817150009100_bnac031-B475","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cca.2016.07.005","article-title":"Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy","volume":"460","author":"Lumachi","year":"2016","journal-title":"Clin Chim Acta"},{"issue":"2","key":"2023050817150009100_bnac031-B476","first-page":"671","article-title":"Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma","volume":"29","author":"Klepzig","year":"2009","journal-title":"Anticancer Res"},{"issue":"3 Pt 1","key":"2023050817150009100_bnac031-B477","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.juro.2007.05.029","article-title":"Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach","volume":"178","author":"Koopmans","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"2023050817150009100_bnac031-B478","first-page":"89","article-title":"Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer","volume":"35","author":"Westerhuis","year":"1997","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"Suppl","key":"2023050817150009100_bnac031-B479","first-page":"C140","article-title":"Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review and meta-analysis","volume":"10","author":"Du","year":"2014","journal-title":"J Cancer Res Ther"},{"issue":"4","key":"2023050817150009100_bnac031-B480","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clon.2012.11.004","article-title":"Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses","volume":"25","author":"Lipton","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"22","key":"2023050817150009100_bnac031-B481","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023050817150009100_bnac031-B482","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-0981-1","article-title":"Prognostic factors for skeletal complications from metastatic bone disease in breast cancer","volume":"123","author":"Brown","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2023050817150009100_bnac031-B483","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2023050817150009100_bnac031-B484","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jbo.2013.01.002","article-title":"Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-an exploratory analysis of placebo-controlled trials","volume":"2","author":"Coleman","year":"2013","journal-title":"J Bone Oncol"},{"issue":"3","key":"2023050817150009100_bnac031-B485","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2023050817150009100_bnac031-B486","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"2023050817150009100_bnac031-B487","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.09.001","article-title":"The role of biomarkers in the management of bone-homing malignancies","volume":"9","author":"D\u2019Oronzo","year":"2017","journal-title":"J Bone Oncol"},{"issue":"11","key":"2023050817150009100_bnac031-B488","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"issue":"6","key":"2023050817150009100_bnac031-B489","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2023050817150009100_bnac031-B490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"2023050817150009100_bnac031-B491","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1681\/ASN.2006050546","article-title":"Association of kidney function with incident hip fracture in older adults","volume":"18","author":"Fried","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2023050817150009100_bnac031-B492","doi-asserted-by":"crossref","first-page":"c256","DOI":"10.1159\/000317207","article-title":"Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis","volume":"116","author":"Kinsella","year":"2010","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"2023050817150009100_bnac031-B493","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.ajkd.2020.02.450","article-title":"Risks of hip and nonvertebral fractures in patients with CKD G3a-G5D: a systematic review and meta-analysis","volume":"76","author":"Vilaca","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023050817150009100_bnac031-B494","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1046\/j.1523-1755.63.s85.13.x","article-title":"The renal osteodystrophy pattern in Brazil and Uruguay: an overview","volume":"85","author":"Araujo","year":"2003","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"2023050817150009100_bnac031-B495","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.transproceed.2007.10.001","article-title":"Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients","volume":"39","author":"Lehmann","year":"2007","journal-title":"Transplant Proc"},{"issue":"4","key":"2023050817150009100_bnac031-B496","first-page":"284","article-title":"Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years","volume":"70","author":"Malluche","year":"2008","journal-title":"Clin Nephrol"},{"issue":"11","key":"2023050817150009100_bnac031-B497","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1093\/ndt\/gfab239","article-title":"Patterns of renal osteodystrophy one year after kidney transplantation","volume":"36","author":"Jorgensen","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2023050817150009100_bnac031-B498","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.2215\/CJN.08241109","article-title":"Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism","volume":"5","author":"Evenepoel","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2023050817150009100_bnac031-B499","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1210\/endo.134.3.8119177","article-title":"Metabolism of N-terminal and C-terminal parathyroid hormone fragments by isolated perfused rat kidney and liver","volume":"134","author":"Daugaard","year":"1994","journal-title":"Endocrinology"},{"issue":"2","key":"2023050817150009100_bnac031-B500","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0085-2538(15)47156-X","article-title":"A novel mechanism for skeletal resistance in uremia","volume":"58","author":"Slatopolsky","year":"2000","journal-title":"Kidney Int"},{"issue":"7","key":"2023050817150009100_bnac031-B501","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1681\/ASN.2005101136","article-title":"Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands","volume":"17","author":"Huan","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2023050817150009100_bnac031-B502","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1210\/jc.2014-1414","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop","volume":"99","author":"Eastell","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023050817150009100_bnac031-B503","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2001.00949.x","article-title":"Improved assessment of bone turnover by the PTH-(1-84)\/large C-PTH fragments ratio in ESRD patients","volume":"60","author":"Monier-Faugere","year":"2001","journal-title":"Kidney Int"},{"issue":"2","key":"2023050817150009100_bnac031-B504","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/ajkd.2002.34519","article-title":"PTH 1-84 and PTH \u201c7-84\u201d in the noninvasive diagnosis of renal bone disease","volume":"40","author":"Coen","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2023050817150009100_bnac031-B505","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5414\/CNP70296","article-title":"Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3-5","volume":"70","author":"Lehmann","year":"2008","journal-title":"Clin Nephrol"},{"issue":"Pt 1","key":"2023050817150009100_bnac031-B506","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1258\/acb.2011.011094","article-title":"Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease","volume":"49","author":"Almond","year":"2012","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"2023050817150009100_bnac031-B507","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","article-title":"Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis","volume":"67","author":"Sprague","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2023050817150009100_bnac031-B508","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ki.2012.77","article-title":"Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients","volume":"82","author":"Sardiwal","year":"2012","journal-title":"Kidney Int"},{"issue":"2","key":"2023050817150009100_bnac031-B509","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.2008.03187.x","article-title":"Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction","volume":"69","author":"Yamada","year":"2008","journal-title":"Clin Endocrinol"},{"key":"2023050817150009100_bnac031-B510","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"2023050817150009100_bnac031-B511","doi-asserted-by":"crossref","first-page":"e10353","DOI":"10.1002\/jbm4.10353","article-title":"A microRNA approach to discriminate cortical low bone turnover in renal osteodystrophy","volume":"4","author":"Nickolas","year":"2020","journal-title":"JBMR Plus"},{"issue":"5","key":"2023050817150009100_bnac031-B512","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.kint.2020.12.024","article-title":"Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease","volume":"99","author":"Ursem","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"2023050817150009100_bnac031-B513","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.ajkd.2015.02.323","article-title":"Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study","volume":"66","author":"Haarhaus","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2023050817150009100_bnac031-B514","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00774-003-0476-9","article-title":"Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover","volume":"22","author":"Alvarez","year":"2004","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"2023050817150009100_bnac031-B515","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1210\/jcem-57-5-1028","article-title":"Effect of renal function on plasma levels of bone Gla-protein","volume":"57","author":"Delmas","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023050817150009100_bnac031-B516","doi-asserted-by":"crossref","first-page":"c78","DOI":"10.1159\/000083418","article-title":"Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients","volume":"99","author":"Nakashima","year":"2005","journal-title":"Nephron Clin Pract"},{"issue":"5","key":"2023050817150009100_bnac031-B517","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00198-004-1712-4","article-title":"Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients","volume":"16","author":"Okuno","year":"2005","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"2023050817150009100_bnac031-B518","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.bone.2009.03.663","article-title":"Usefulness of bone resorption markers in hemodialysis patients","volume":"45","author":"Hamano","year":"2009","journal-title":"Bone"},{"issue":"9","key":"2023050817150009100_bnac031-B519","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/ndt\/13.9.2294","article-title":"Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients","volume":"13","author":"Coen","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"Pt 1","key":"2023050817150009100_bnac031-B520","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1258\/acb.2009.009110","article-title":"Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide","volume":"47","author":"Koivula","year":"2010","journal-title":"Ann Clin Biochem"},{"issue":"12","key":"2023050817150009100_bnac031-B521","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"issue":"8","key":"2023050817150009100_bnac031-B522","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","article-title":"Rapid cortical bone loss in patients with chronic kidney disease","volume":"28","author":"Nickolas","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023050817150009100_bnac031-B523","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12882-017-0692-5","article-title":"Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study","volume":"18","author":"Jorgensen","year":"2017","journal-title":"BMC Nephrol"},{"issue":"8","key":"2023050817150009100_bnac031-B524","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.2010121275","article-title":"Discriminants of prevalent fractures in chronic kidney disease","volume":"22","author":"Nickolas","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2023050817150009100_bnac031-B525","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.kint.2018.12.024","article-title":"Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients","volume":"95","author":"Evenepoel","year":"2019","journal-title":"Kidney Int"},{"issue":"10","key":"2023050817150009100_bnac031-B526","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/ajt.12425","article-title":"Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation","volume":"13","author":"Perrin","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"2023050817150009100_bnac031-B527","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2013080851","article-title":"Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton","volume":"25","author":"Iyer","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2023050817150009100_bnac031-B528","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2220\/biomedres.39.131","article-title":"Effects of the calcineurin inhibitors cyclosporine and tacrolimus on bone metabolism in rats","volume":"39","author":"Kanda","year":"2018","journal-title":"Biomed Res"},{"issue":"1","key":"2023050817150009100_bnac031-B529","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","article-title":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2013a single-center cohort study","volume":"27","author":"Iimori","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2023050817150009100_bnac031-B530","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1681\/ASN.V73506","article-title":"Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients","volume":"7","author":"Urena","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2023050817150009100_bnac031-B531","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","article-title":"Denosumab safety and efficacy among subjects in the FREEDOM extension study with mild-to-moderate chronic kidney disease","volume":"106","author":"Broadwell","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023050817150009100_bnac031-B532","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int"},{"issue":"12","key":"2023050817150009100_bnac031-B533","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023050817150009100_bnac031-B534","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2023050817150009100_bnac031-B535","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2023050817150009100_bnac031-B536","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2023050817150009100_bnac031-B537","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2023050817150009100_bnac031-B538","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/jbmr.3676","article-title":"Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial","volume":"34","author":"Iseri","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2023050817150009100_bnac031-B539","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/ajt.13692","article-title":"Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial","volume":"16","author":"Bonani","year":"2016","journal-title":"Am J Transplant"},{"key":"2023050817150009100_bnac031-B540","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/CIA.S120175","article-title":"Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study","volume":"11","author":"Nishikawa","year":"2016","journal-title":"Clin Interv Aging"},{"issue":"3","key":"2023050817150009100_bnac031-B541","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000316708","article-title":"Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study","volume":"33","author":"Cejka","year":"2010","journal-title":"Kidney Blood Pressure Res"},{"issue":"3","key":"2023050817150009100_bnac031-B542","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000341864","article-title":"Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study","volume":"36","author":"Mitsopoulos","year":"2012","journal-title":"Am J Nephrol"},{"issue":"2","key":"2023050817150009100_bnac031-B543","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/1744-9987.12867","article-title":"Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study","volume":"24","author":"Yamamoto","year":"2020","journal-title":"Ther Apher Dial"},{"issue":"4","key":"2023050817150009100_bnac031-B544","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","article-title":"Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study","volume":"27","author":"Sumida","year":"2016","journal-title":"Osteoporos Int"},{"issue":"9","key":"2023050817150009100_bnac031-B545","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1600-6143.2008.02327.x","article-title":"Effect of teriparatide on early bone loss after kidney transplantation","volume":"8","author":"Cejka","year":"2008","journal-title":"Am J Transplant"},{"issue":"7","key":"2023050817150009100_bnac031-B546","first-page":"CD013424","article-title":"Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D","volume":"7","author":"Hara","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2023050817150009100_bnac031-B547","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"166","author":"Wilson","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"2023050817150009100_bnac031-B548","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol Dial Transplant"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnac031\/49016132\/bnac031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/44\/3\/417\/50248389\/bnac031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/44\/3\/417\/50248389\/bnac031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T03:48:24Z","timestamp":1728532104000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/44\/3\/417\/6889555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":548,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12,13]]},"published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnac031","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2022,12,13]]}}}